World's Best Scientists 2026 revealed!
Richard T. Silver

Richard T. Silver

D-Index & Metrics

Medicine

D-Index
85
Citations
42335
World Ranking
14376
National Ranking
7269

Overview

Richard T. Silver is affiliated with Cornell University in the United States. Their body of research primarily focuses on the medical field, with significant contributions in genetics, hematology, rheumatology, molecular biology, and oncology. Their scholarly output reflects a consistent engagement with disease mechanisms and treatments related to blood disorders and malignancies.

The main topics covered in their research include:

  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Eosinophilic Disorders and Syndromes
  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • Kruppel-like factors research
  • Chronic Lymphocytic Leukemia Research
  • Hemoglobinopathies and Related Disorders

Frequent coauthors who have collaborated with Richard T. Silver include:

  • Ghaith Abu-Zeinah
  • Joseph M. Scandura
  • Katie Erdos
  • Ellen K. Ritchie
  • Elwood Taylor

The scientist has published extensively in several journals, notably in:

  • Blood
  • Leukemia
  • Blood Advances
  • Haematologica
  • bioRxiv (Cold Spring Harbor Laboratory)

Among the recent notable publications are:

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia, 2020, Leukemia
  • Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure, 2020, American Journal of Hematology
  • Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival, 2021, Leukemia
  • Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia, 2020, JAMA Oncology
  • Normal life expectancy for polycythemia vera (PV) patients is possible, 2021, Leukemia

Best Publications

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

    Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy

  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

    Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

    Amy V. Jones;Sebastian Kreil;Katerina Zoi;Katherine Waghorn

  • Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

    Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes

  • Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

    Andreas Hochhaus;Hagop M. Kantarjian;Michele Baccarani;Jeffrey H. Lipton

  • Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults.

    Rose Ruth Ellison;James F. Holland;Marise Weil;Claude Jacquillat

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

    Oliver G. Ottmann;Brian J. Druker;Charles L. Sawyers;John M. Goldman

  • Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

    Neil P. Shah;Hagop M. Kantarjian;Dong Wook Kim;Delphine Réa

  • Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study

    J Yates;O Glidewell;P Wiernik;Cooper

  • Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.

    KR Rai;JF Holland;OJ Glidewell;V Weinberg

  • An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology

    Richard T. Silver;Steven H. Woolf;Rüdiger Hehlmann;Frederick R. Appelbaum

  • Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet

    Tiziano Barbui;Ayalew Tefferi;Alessandro M. Vannucchi;Francesco Passamonti

  • Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

    A. Hochhaus;M. Baccarani;M. Deininger;J. F. Apperley

  • JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.

    Amy V Jones;Andrew Chase;Richard T Silver;David Oscier

Frequent Co-Authors

Morton Coleman
Morton Coleman Cornell University
Ruben A. Mesa
Ruben A. Mesa The University of Texas Health Science Center at San Antonio
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Alessandro M. Vannucchi
Alessandro M. Vannucchi University of Florence
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Jason Gotlib
Jason Gotlib Stanford University
Michael W. Deininger
Michael W. Deininger University of Utah
Francisco Cervantes
Francisco Cervantes University of Barcelona
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Nicholas C.P. Cross
Nicholas C.P. Cross University of Southampton

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in pursuing medicine in the USA, there are several online pathways and degrees that can help launch or advance your healthcare career. Online programs offer the flexibility to balance education with work or family commitments, and many are designed to be affordable and accessible.

For those just beginning, exploring what is the cheapest online college for nursing? can help you start your nursing education without a significant financial burden. Many accredited programs offer flexible schedules and lower tuition rates for online learners.

If you're already a registered nurse (RN), you might consider advancing your credentials with one of the cheapest accredited online rn to bsn programs. These bridge programs are specifically designed to build upon prior nursing experience and often take less time to complete.

Those interested in leadership, research, or advanced clinical practice roles may want to look into earning an online nursing doctorate. Doctoral degrees can open doors to teaching positions and specialized fields within healthcare.

Even non-nurses can enter the field through online direct entry msn programs for non-nurses, which offer a fast-track route for those with a non-nursing bachelor’s degree.

Best Scientists Citing Richard T. Silver

Trending Scientists

Recently Published Articles